Ironwood Pharmaceuticals (IRWD) Convertible Debt (2015 - 2025)

Ironwood Pharmaceuticals (IRWD) has 11 years of Convertible Debt data on file, last reported at $199.2 million in Q1 2025.

• For the quarter ending Q1 2025, Convertible Debt changed 0.34% year-over-year to $199.2 million; the trailing twelve-month figure through Mar 2025 stood at $199.2 million (changed 0.34% YoY), and the FY2024 full-year result was $199.0 million, changed 0.34% from the prior year.
• Convertible Debt was little changed at $199.2 million in Q1 2025, from $199.0 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $436.1 million in Q1 2021 to a low of $198.0 million in Q2 2023.
• A 5-year average of $294.3 million and a median of $329.2 million in 2021 frame the typical range for Convertible Debt.
• Across the five-year window, Convertible Debt rose 20.14% in 2022 and tumbled 49.96% in 2024, its largest moves.
• Tracing IRWD's Convertible Debt over 5 years: stood at $337.3 million in 2021, then grew by 17.47% to $396.3 million in 2022, then sank by 49.95% to $198.3 million in 2023, then rose by 0.34% to $199.0 million in 2024, then gained by 0.09% to $199.2 million in 2025.
• Business Quant data shows IRWD's Convertible Debt at $199.2 million in Q1 2025, $199.0 million in Q4 2024, and $198.8 million in Q3 2024.